[go: up one dir, main page]

MX2019012876A - Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina. - Google Patents

Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina.

Info

Publication number
MX2019012876A
MX2019012876A MX2019012876A MX2019012876A MX2019012876A MX 2019012876 A MX2019012876 A MX 2019012876A MX 2019012876 A MX2019012876 A MX 2019012876A MX 2019012876 A MX2019012876 A MX 2019012876A MX 2019012876 A MX2019012876 A MX 2019012876A
Authority
MX
Mexico
Prior art keywords
cysteine engineered
domain containing
cysteine
binding molecules
type iii
Prior art date
Application number
MX2019012876A
Other languages
English (en)
Inventor
GOLDBERG Shalom
Lin Tricia
Jacobs Steven
O´Neil Karyn
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2019012876A publication Critical patent/MX2019012876A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las moleculas monoespecificas y biespecificas que contienen dominios de FN3 de EGFR y/o c-Met modificados con cisteina que comprenden uno o más aminoacidos de cisteina libre se preparan por mutagenesis de una secuencia de ácido nucleico de una molecula parental y al reemplazar uno o más residuos de aminoacidos por cisteina para codificar las moléculas monoespecificas o biespecificas que contienen el dominio de FN3 modificado con cisteina; expresar las moleculas que contienen dominios de FN3 modificados con cisteina; y recuperar la molecula que contiene dominios de FN3 modificados con cisteina; las moleculas monoespecificas y biespecificas aisladas que contienen dominios de FN3 modificados con cisteina pueden unirse covalentemente a una etiqueta de deteccion o a una porcion de farmaco y usarse terapeuticamente.
MX2019012876A 2013-10-14 2016-04-14 Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina. MX2019012876A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361890539P 2013-10-14 2013-10-14

Publications (1)

Publication Number Publication Date
MX2019012876A true MX2019012876A (es) 2019-12-11

Family

ID=52809988

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004862A MX378238B (es) 2013-10-14 2014-10-13 Moléculas de unión con dominios de fibronectina de tipo iii modificadas con cisteína.
MX2019012876A MX2019012876A (es) 2013-10-14 2016-04-14 Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016004862A MX378238B (es) 2013-10-14 2014-10-13 Moléculas de unión con dominios de fibronectina de tipo iii modificadas con cisteína.

Country Status (12)

Country Link
US (3) US10196446B2 (es)
EP (1) EP3057608B1 (es)
JP (2) JP6585040B2 (es)
KR (2) KR102478402B1 (es)
CN (1) CN105899226B (es)
AU (2) AU2014334627B2 (es)
BR (1) BR112016008125B1 (es)
CA (1) CA2926262C (es)
EA (1) EA035745B1 (es)
IL (1) IL244623B (es)
MX (2) MX378238B (es)
WO (1) WO2015057545A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR102478402B1 (ko) 2013-10-14 2022-12-15 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
US20190144503A1 (en) * 2016-04-27 2019-05-16 Regents Of The University Of Minnesota Methods for the identification of bifunctional compounds
SG11201811062XA (en) * 2016-06-21 2019-01-30 Janssen Biotech Inc Cysteine engineered fibronectin type iii domain binding molecules
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
BR112019012154A2 (pt) 2016-12-14 2019-11-12 Janssen Biotech, Inc. domínios do tipo iii da fibronectina de ligação a cd8a
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
CN108743966B (zh) * 2018-04-24 2021-10-19 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108640982A (zh) * 2018-05-21 2018-10-12 华东师范大学 一种重组含双发色团光受体蛋白古紫质4及其构建方法和应用
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
JP7703541B2 (ja) 2019-12-18 2025-07-07 アロ・バイオセラピューティクス・カンパニー 血清アルブミン結合性フィブロネクチンｉｉｉ型ドメインおよびその使用
CA3215367A1 (en) 2021-04-14 2022-10-20 Swapnil Kulkarni Fn3 domain-sirna conjugates and uses thereof
EP4323409A4 (en) 2021-04-14 2025-04-16 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
TWI836609B (zh) * 2022-09-16 2024-03-21 國立成功大學 纖維黏蛋白第iii型結構域衍生的蛋白質及其應用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE168416T1 (de) 1989-10-05 1998-08-15 Optein Inc Zellfreie synthese und isolierung von genen und polypeptiden
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5846456A (en) 1996-01-17 1998-12-08 National Science Council Method of making gradient index optical element
DE69839147T2 (de) 1997-06-12 2009-02-19 Novartis International Pharmaceutical Ltd. Künstliche antikörperpolypeptide
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
WO2003037365A1 (en) 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
DK1534830T3 (da) 2002-09-06 2011-02-14 Isogenica Ltd In vito-peptid-ekspressionsbibliotek
WO2004093892A2 (en) 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
CA2569520C (en) 2004-06-04 2023-03-14 Genentech, Inc. Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab
EP2163563A1 (en) 2006-03-31 2010-03-17 Massachusetts Institute of Technology Treatment of tumors expressing mutant EGF receptors
AU2008216495A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
CA2710373A1 (en) 2007-12-19 2009-07-09 Ping Tsui Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
CA2710378A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
AU2008345424A1 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
KR20100135780A (ko) 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
CL2009000843A1 (es) 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
PT2274331E (pt) * 2008-05-02 2014-02-27 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
ES2564055T3 (es) 2008-05-30 2016-03-17 Genentech, Inc. Variante de la proteína Hhip1 y métodos y usos de la misma
EP2349328A1 (en) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
AU2009299791B2 (en) 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
JP5612663B2 (ja) 2009-04-07 2014-10-22 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
CA3254586A1 (en) 2010-03-10 2025-11-29 Genmab A/S Monoclonal anti bodi es against c-met
AU2011240620A1 (en) * 2010-04-13 2012-10-18 Medimmune, Llc Fibronectin type III domain-based multimeric scaffolds
ES2989108T3 (es) 2010-04-20 2024-11-25 Genmab As Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
TW201742925A (zh) 2010-04-23 2017-12-16 建南德克公司 異多聚體蛋白質之製造
PT3103478T (pt) * 2010-04-30 2019-07-10 Janssen Biotech Inc Composições, métodos e utilizações de domínios de fibronectinas estabilizadas
EP3091028A1 (en) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
WO2012162426A1 (en) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heptameric targeting ligands
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR20250054125A (ko) 2012-11-21 2025-04-22 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
KR102478402B1 (ko) 2013-10-14 2022-12-15 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
KR102461666B1 (ko) 2016-06-03 2022-11-01 얀센 바이오테크 인코포레이티드 혈청 알부민 결합 피브로넥틴 iii 형 도메인

Also Published As

Publication number Publication date
AU2019253863A1 (en) 2019-11-14
KR102478402B1 (ko) 2022-12-15
IL244623A0 (en) 2016-04-21
WO2015057545A3 (en) 2015-06-11
BR112016008125B1 (pt) 2023-11-21
BR112016008125A2 (pt) 2017-12-26
MX2016004862A (es) 2016-08-01
EA035745B1 (ru) 2020-08-05
US11702475B2 (en) 2023-07-18
CA2926262A1 (en) 2015-04-23
IL244623B (en) 2022-08-01
CN105899226B (zh) 2020-05-12
EA201690773A1 (ru) 2016-08-31
EP3057608B1 (en) 2025-12-10
MX378238B (es) 2025-03-10
KR20220136463A (ko) 2022-10-07
JP2020011969A (ja) 2020-01-23
JP6585040B2 (ja) 2019-10-02
CA2926262C (en) 2025-06-17
WO2015057545A2 (en) 2015-04-23
EP3057608A2 (en) 2016-08-24
US20210301025A1 (en) 2021-09-30
US20150104808A1 (en) 2015-04-16
US20190263915A1 (en) 2019-08-29
US11072663B2 (en) 2021-07-27
AU2014334627B2 (en) 2019-07-25
AU2014334627A1 (en) 2016-04-07
AU2019253863B2 (en) 2022-03-10
CN105899226A (zh) 2016-08-24
KR20160067966A (ko) 2016-06-14
JP2017500003A (ja) 2017-01-05
EP3057608A4 (en) 2017-10-11
US10196446B2 (en) 2019-02-05

Similar Documents

Publication Publication Date Title
MX2019012876A (es) Moleculas de union con dominios de fibronectina de tipo iii modificadas con cisteina.
MX2018016185A (es) Moléculas de unión al dominio de fibronectina tipo iii diseñadas de cisteína.
MX374682B (es) Moléculas de unión a 4-1bb.
MY195318A (en) Multispecific Antibody Constructs
EP4270006A3 (en) General detection and isolation of specific cells by binding of labeled molecules
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
PH12015501651B1 (en) Antibody constructs for cdh19 and cd3
UA106586C2 (uk) Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
PH12015501672A1 (en) Binding molecules for bcma and cd3
UA116632C2 (uk) Химерний білок, який містить фактор viii та фактор віллебранда, і його застосування
GB2537077A (en) Methods for sequencing nucleic acids
EP2271586A4 (en) PROCESS FOR PRODUCING CARBON NANOSTRUCTURES
AR104358A1 (es) Método para la purificación de proteínas
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
GB201214580D0 (en) Benzocyanine compounds
MX2016000393A (es) Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
PH12015500107A1 (en) Process for designing diverged, condon-optimized large repeated dna sequences
PH12017500309A1 (en) Anti-vasa antibodies, and methods of production and use thereof
EP2259269A4 (en) METHOD FOR MANUFACTURING RADIOACTIVE STRONTIUM
EP2554672A4 (en) NUCLEIC ACID STRUCTURE, METHOD FOR PRODUCING A COMPLEX AND SCREENING METHOD THEREFOR
WO2014058982A3 (en) Nuclear factor-erythroid 2 related factor 2 (nrf2) biosensors and modulators of nrf2
CY1117137T1 (el) 2-amino-3-methyl-hex-5-enoic acid και η χρηση του στην παραγωγη πεπτιδιων οπως bacitracins
TH129827A (th) เปปไทด์ที่ติดฉลากด้วยโมเลกุลติดตามเพื่อการตรวจจับโปรตีน P16 ink4a และกรรมวิธีการใช้เปปไทด์ดังกล่าว
NZ733839A (en) Amino acid and peptide conjugates and conjugation process
AR097922A1 (es) Exotoxina a de pseudomonas modificada